Design Therapeutics, Inc. - Common Stock (DSGN)

Historical Holders from Q1 2021 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
DSGN on Nasdaq
Shares outstanding
57,159,091
Price per share
$9.38
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
34,492,564
Total reported value
$259,728,206
% of total 13F portfolios
0%
Share change
-39,040
Value change
+$644,096
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
94
Price from insider filings
$5.25
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Design Therapeutics, Inc. - Common Stock (DSGN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Light Irrevocable Trust #1 dated April 22, 2019 6.9% $14,800,610 3,834,355 Light Irrevocable Trust #1 dated April 22, 2019 31 Dec 2024
Star Irrevocable Trust #1 dated April 22, 2019 6.9% $14,800,610 3,834,355 Star Irrevocable Trust #1 dated April 22, 2019 31 Dec 2024
Point72 Asset Management, L.P. 5.2% $16,596,935 2,942,719 Point72 Asset Management, L.P. 27 Aug 2025
Logos Global Management LP 4.4% -22% $16,322,350 -$4,802,600 2,515,000 -23% Arsani William 14 Nov 2025
As of 30 Sep 2025, Design Therapeutics, Inc. - Common Stock (DSGN) has 94 institutional shareholders filing 13F forms. They hold 34,492,564 shares. of 57,159,091 outstanding shares (60%) .

Top 25 institutional shareholders own 57% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
SR One Capital Management, LP 11% 6,526,476 0% 7.1% $49,144,364
Logos Global Management LP 6.4% 3,655,000 -13% 2.7% $27,522,150
Point72 Asset Management, L.P. 5.8% 3,340,552 +85% 0.05% $25,154,353
BlackRock, Inc. 3.6% 2,044,388 -15% 0% $15,394,241
Frazier Life Sciences Management, L.P. 3.4% 1,953,547 0% 0.44% $14,710,209
TANG CAPITAL MANAGEMENT LLC 3.1% 1,780,975 0% 0.52% $13,410,742
BAKER BROS. ADVISORS LP 3% 1,712,882 0% 0.09% $12,898,001
Almitas Capital LLC 2.7% 1,530,435 0% 2.6% $11,524,176
VANGUARD GROUP INC 2.5% 1,443,701 -1.9% 0% $10,871,069
Driehaus Capital Management LLC 1.9% 1,076,236 0% 0.06% $8,104,057
Kynam Capital Management, LP 1.8% 1,029,579 0% 0.58% $7,752,730
FMR LLC 1.3% 740,849 -22% 0% $5,578,593
GEODE CAPITAL MANAGEMENT, LLC 1.2% 695,613 -12% 0% $5,239,165
STATE STREET CORP 1.1% 634,397 -12% 0% $4,777,009
ACADIAN ASSET MANAGEMENT LLC 1.1% 617,489 -1.6% 0.01% $4,648,000
Woodline Partners LP 1.1% 612,712 -21% 0.02% $4,613,721
MPM BIOIMPACT LLC 0.97% 555,187 0% 0.68% $4,180,558
CITADEL ADVISORS LLC 0.97% 554,020 -34% 0% $4,171,771
RA CAPITAL MANAGEMENT, L.P. 0.83% 475,699 0.04% $3,582,013
D. E. Shaw & Co., Inc. 0.65% 373,276 -4.4% 0% $2,810,768
NORTHERN TRUST CORP 0.52% 296,529 -18% 0% $2,232,864
DIMENSIONAL FUND ADVISORS LP 0.49% 279,817 -11% 0% $2,105,397
RENAISSANCE TECHNOLOGIES LLC 0.48% 274,300 +2.4% 0% $2,065,479
GOLDMAN SACHS GROUP INC 0.46% 261,445 +9.2% 0% $1,968,681
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.43% 247,934 -1.2% 0% $1,866,943

Institutional Holders of Design Therapeutics, Inc. - Common Stock (DSGN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 990 $9,287 +$2,355 938.08% 3
2025 Q3 34,492,564 $259,728,206 +$644,096 753% 94
2025 Q2 34,530,294 $116,365,282 +$265,376 337% 91
2025 Q1 34,459,430 $133,014,347 +$2,133,111 386% 95
2024 Q4 33,460,789 $206,452,272 +$9,368,483 617% 94
2024 Q3 32,032,058 $172,330,117 +$1,330,353 538% 99
2024 Q2 32,097,220 $107,523,400 +$4,413,894 335% 92
2024 Q1 30,700,544 $123,722,440 -$2,844,064 403% 88
2023 Q4 14,090 $37,339 -$110,212 265% 1
2023 Q3 32,867,255 $77,567,559 -$68,498,746 236% 84
2023 Q2 38,786,588 $244,358,601 +$735,436 630% 96
2023 Q1 38,691,853 $223,252,544 -$16,075,749 577% 97
2022 Q4 40,364,253 $414,121,139 -$490,145 1,026% 80
2022 Q3 39,906,346 $667,243,062 +$24,296,112 1,672% 76
2022 Q2 38,548,830 $539,687,132 +$8,622,378 1,400% 67
2022 Q1 32,363,756 $522,852,140 +$27,797,027 1,615% 60
2021 Q4 30,543,417 $652,659,906 +$50,178,002 2,141% 56
2021 Q3 28,281,317 $414,830,000 +$5,453,146 1,469.01% 52
2021 Q2 27,832,674 $546,067,000 +$37,361,092 1,988.88% 48
2021 Q1 25,762,953 $755,185,000 +$755,158,108 2,990% 43